Table 1.

Clinical trials in patients with hypertension demonstrating a blood pressure–lowering effects of LCZ696 vs a comparator

Author	Patients, No.	Age,y	Follow‐up, wk	SBP, mm Hg	∆, mm Hg	DBP, mm Hg	∆, mm Hg
Drug dose, mg
Ruilope1
LCZ696 100	156	53	8	155	−3.2	100	−4.7
LCZ696 200	169	54	8	157	−11.0	100	−6.1
LCZ696 400	172	53	8	155	−12.5	100	−6.9
Valsartan 80	163	53	8	155	−4.7	100	−2.4
Valsartan 160	166	53	8	155	−5.7	100	−3.2
Valsartan 320	164	53	8	156	−12.5	100	−4.2
Kario8
LCZ696 100	100	3	8	156	−11.5	100	−4.7
LCZ696 200	101	52	8	156	−11.0	100	−6.5
LCZ696 400	96	51	8	154	−12.5	100	−7.8
Kario10
LCZ696 200	35	51	4	173	−23.1	112	−14
LCZ696 400	32	51	8	173	−35.3	112	−22.1
Ito11
LCZ696 100	32	66	4	152	−13.4	87	−5.2
LCZ696 200	26	66	6	152	−19.4	87	−7.8
LCZ696 400	18	66	8	152	−20.7	87	−8.4
Wang12
LCZ696 200 + amlodipine 5 Amlodipine 5	123	55	8	138	−13.9	86	−0.8
	128	55	8	140	−8.0	86	−0.3
Wang13
LCZ696 400	36	56	8	147	−13.3	90	−6.2
Valsartan 320	36	59	8	148	−5.8	90	−4.2
Williams14
LCZ696 400	207	68	12	158	−13.7	87	−5.9
Olmesartan 40	206	67	12	159	−9.9	90	−4.9
LCZ696 400	209	68	52	158	−17.7	87	−8.7
Olmesartan 40	208	67	52	159	−16.1	90	−8.1

Abbreviations: ∆, change from baseline; DBP, diastolic blood pressure; SBP, systolic blood pressure.